MX387604B - Formulaciones cannabinoides estables. - Google Patents

Formulaciones cannabinoides estables.

Info

Publication number
MX387604B
MX387604B MX2016015636A MX2016015636A MX387604B MX 387604 B MX387604 B MX 387604B MX 2016015636 A MX2016015636 A MX 2016015636A MX 2016015636 A MX2016015636 A MX 2016015636A MX 387604 B MX387604 B MX 387604B
Authority
MX
Mexico
Prior art keywords
stable
cannabinoid formulations
formulation
cannabinoid
stable cannabinoid
Prior art date
Application number
MX2016015636A
Other languages
English (en)
Other versions
MX2016015636A (es
Inventor
Huaguang Li
Hung Q Nguyen
Kiran Kumar Vangara
Ningxin Yin
Venkat R Goskonda
Original Assignee
Insys Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insys Pharma Inc filed Critical Insys Pharma Inc
Publication of MX2016015636A publication Critical patent/MX2016015636A/es
Publication of MX387604B publication Critical patent/MX387604B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención generalmente se dirige a cannabidiol sustancialmente puro, formulaciones farmacéuticas cannabinoides estables, y métodos de su uso; en un aspecto, la presente invención se dirige a formulaciones farmacéuticas estables para administración oral que comprenden de aproximadamente 0.1 a aproximadamente 50% de un cannabinoide, de aproximadamente 0.1 a aproximadamente 40% de un polietilenglicol, de aproximadamente 0.1 a aproximadamente 50% de propilenglicol; y de aproximadamente 0.1 a aproximadamente 20% de agua, en donde la formulación no contiene alcohol y la formulación tiene un pH de aproximadamente 5 a aproximadamente 8.
MX2016015636A 2014-05-29 2015-05-28 Formulaciones cannabinoides estables. MX387604B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004495P 2014-05-29 2014-05-29
US201562154660P 2015-04-29 2015-04-29
PCT/US2015/032955 WO2015184127A2 (en) 2014-05-29 2015-05-28 Stable cannabinoid formulations

Publications (2)

Publication Number Publication Date
MX2016015636A MX2016015636A (es) 2017-08-02
MX387604B true MX387604B (es) 2025-03-18

Family

ID=54700061

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015636A MX387604B (es) 2014-05-29 2015-05-28 Formulaciones cannabinoides estables.
MX2021006035A MX2021006035A (es) 2014-05-29 2016-11-28 Formulaciones cannabinoides estables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006035A MX2021006035A (es) 2014-05-29 2016-11-28 Formulaciones cannabinoides estables.

Country Status (12)

Country Link
US (4) US11224660B2 (es)
EP (2) EP3148589B8 (es)
JP (1) JP6659933B2 (es)
KR (1) KR20170008311A (es)
CN (2) CN114191420A (es)
AU (1) AU2015266897B2 (es)
CA (1) CA2950424C (es)
IL (2) IL302782A (es)
MX (2) MX387604B (es)
NZ (1) NZ726746A (es)
WO (1) WO2015184127A2 (es)
ZA (1) ZA201608209B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
AU2015266897B2 (en) * 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
GB201508656D0 (en) 2015-05-20 2015-07-01 Sunstone Ip Systems Ltd Portable power generating apparatus
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
GB2544468A (en) * 2015-11-12 2017-05-24 Jaytee Biosciences Ltd Liquid formulation
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2549278B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Use of cannabidivarin in the treatment of autism spectrum disorder
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
WO2017204986A1 (en) 2016-05-27 2017-11-30 Insys Development Company, Inc. Stable cannabinoid formulations
CA3027862A1 (en) * 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
IL265902B2 (en) 2016-10-11 2024-04-01 Gbs Global Biopharma Inc Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018096504A1 (en) * 2016-11-28 2018-05-31 Kalytera Therapeutics, Inc Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN107753560A (zh) * 2016-12-28 2018-03-06 汉义生物科技（北京）有限公司 一种含大麻提取物的组合物及应用
JP7225104B2 (ja) 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
NL2018504B1 (en) * 2017-03-13 2018-09-21 Pharma Unlimited B V Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction
WO2018200024A1 (en) 2017-04-27 2018-11-01 Insys Development Company, Inc. Stable cannabinoid formulations
GB2564383B (en) * 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019018705A1 (en) * 2017-07-21 2019-01-24 Masaya World, Llc CAPRYLIC ACID ENRICHED IN CANNABIDIOL
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
AU2018343256B2 (en) 2017-09-28 2024-09-19 Harmony Biosciences Management, Inc. Treatment of Fragile X Syndrome with cannabidiol
GB2568471B (en) * 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2572126B (en) * 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572125B (en) * 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CA3055225A1 (en) 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
BR102018002843A2 (pt) * 2018-02-09 2019-08-27 Prati Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
AU2019263302C1 (en) 2018-05-01 2024-10-31 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
BR112020022083A2 (pt) 2018-05-01 2021-02-02 Chibi, Inc. depot líquido, estojo e método para tratar a retina.
CA3054203C (en) 2018-05-03 2021-01-05 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
CN110575448A (zh) * 2018-06-08 2019-12-17 云南汉素生物科技有限公司 大麻二酚组合物及其用途
CN109627148B (zh) * 2018-11-28 2021-09-03 中国农业科学院麻类研究所 一种大麻二酚的制备方法、制得的大麻二酚及其用途
US20210290562A1 (en) 2018-12-11 2021-09-23 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
JOP20210140A1 (ar) 2018-12-14 2023-01-30 Zynerba Pharmaceuticals Inc معالجة متلازمة الحذف 22q11.2 بكانابيديول
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
US12440501B2 (en) 2019-02-08 2025-10-14 Srin Therapeutics, Inc. Cannabinoid compositions and methods of use thereof for immune modulation
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
MX2022001634A (es) * 2019-08-08 2022-05-11 Neptune Wellness Solutions Inc Formulaciones orales de extractos de cannabis y metodos para elaborar las mismas.
EP4017485A1 (en) * 2019-08-22 2022-06-29 EPM Group, Inc. Cannabinoid acid ester compositions and uses thereof
CN111202767A (zh) * 2019-09-04 2020-05-29 汉义生物科技（北京）有限公司 大麻全草提取物在改善tau蛋白和β-淀粉样蛋白病理损伤中应用
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
ES3060000T3 (en) * 2019-09-09 2026-03-24 Cardiol Therapeutics Inc Stable medicinal cannabidiol compositions
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US20210169795A1 (en) * 2019-12-06 2021-06-10 Joshua Steindler Colloidal Suspensions of Plant Extracts in Aqueous Solutions
GB201918846D0 (en) 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
US12350252B2 (en) 2019-12-31 2025-07-08 Soluscience, Llc Water-soluble cannabinoid formulations and methods of their making
CN113087743B (zh) 2020-01-08 2023-04-28 成都百裕制药股份有限公司 四氢大麻酚衍生物及其制备方法和在医药上的应用
US12545694B2 (en) 2020-01-08 2026-02-10 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof
EP4100399A4 (en) * 2020-02-06 2024-11-20 London Pharmaceuticals and Research Corporation Cannabinoid sulfate esters, their salts and uses thereof
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
KR102213253B1 (ko) * 2020-04-29 2021-02-08 한국과학기술원 산화적 스트레스에 대한 칸나비디올의 신경세포 보호 효과 평가 방법 및 칸나비디올을 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
KR20230066372A (ko) * 2020-09-24 2023-05-15 니코벤처스 트레이딩 리미티드 포뮬레이션
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
MX2023006686A (es) * 2020-12-07 2023-06-19 Cardiol Therapeutics Inc Composiciones orales estables de cannabidiol.
JP2024500187A (ja) * 2020-12-21 2024-01-04 アイソセレス ファーマシューティカルズ，インコーポレイテッド 非経口カンナビノイド配合物およびその使用
US11242330B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11242328B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
JP2022164537A (ja) * 2021-04-16 2022-10-27 株式会社東洋新薬 経口組成物
KR102800463B1 (ko) * 2021-04-27 2025-04-30 비조팹 주식회사 Ｃｂｄ 액상 조성물 제조 방법과 이를 함유하는 의료용 제품을 제공하는 텔레메디슨 시스템
CN113398104B (zh) * 2021-07-14 2022-04-08 北京森宏健康科技有限公司 大麻二酚在治疗胆红素脑病中的用途
CA3239914A1 (en) * 2021-12-03 2023-06-08 Avicanna Inc. Oral cannabinoid compositions and methods for treating neurological diseases and disorders
EP4507689A1 (en) 2022-04-12 2025-02-19 Shackelford Pharma Inc. Treatment of seizure disorders
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS
AU2023361756A1 (en) * 2022-10-12 2025-05-22 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
WO2025099099A1 (en) 2023-11-06 2025-05-15 Esolate Pharmaceuticals Limited Novel oral cannabinoid formulations
US20260069611A1 (en) 2024-09-06 2026-03-12 A2W Pharma Limited Stable cannabidiol oral formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023720T2 (de) 1999-08-20 2006-07-20 Unimed Pharmaceuticals, Inc. Zusammensetzung für inhalierung enthaltend delta-9-tetrahydrocannabinol in einem semi-wässrigen lösungsmittel
GB0103638D0 (en) * 2001-02-14 2001-03-28 Gw Pharmaceuticals Ltd Pharmaceutical formulations
NZ527289A (en) 2001-02-14 2005-05-27 Gw Pharma Ltd Lipophilic medicaments and their administration via mucosal surfaces
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
CA2487882A1 (en) * 2002-05-31 2003-12-11 University Of Mississippi Transmucosal delivery of cannabinoids
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
MX2007007038A (es) * 2004-12-09 2008-03-07 Insys Therapeutics Inc Formulacion de dronabinol en temperatura ambiente.
CA2623723A1 (en) * 2005-09-29 2007-04-12 Amr Technology, Inc. Process for production of delta-9-tetrahydrocannabinol
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
AU2015266897B2 (en) * 2014-05-29 2020-07-30 Fresh Cut Development, Llc Stable cannabinoid formulations
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA3140113A1 (en) * 2019-05-15 2020-12-30 Benuvia Manufacturing, Llc Self-emulsifying cannabidiol formulations

Also Published As

Publication number Publication date
EP3148589A4 (en) 2018-01-17
US20220184215A1 (en) 2022-06-16
AU2015266897A1 (en) 2016-12-15
MX2021006035A (es) 2021-07-06
US20220125932A1 (en) 2022-04-28
JP6659933B2 (ja) 2020-03-04
CN106999598B (zh) 2022-02-08
MX2016015636A (es) 2017-08-02
US20150343071A1 (en) 2015-12-03
NZ726746A (en) 2020-08-28
EP3148589B8 (en) 2024-12-04
CA2950424A1 (en) 2015-12-03
EP3148589A2 (en) 2017-04-05
NZ763449A (en) 2024-02-23
US11224660B2 (en) 2022-01-18
EP3148589C0 (en) 2024-10-30
KR20170008311A (ko) 2017-01-23
AU2015266897B2 (en) 2020-07-30
CN114191420A (zh) 2022-03-18
CN106999598A (zh) 2017-08-01
WO2015184127A9 (en) 2016-05-19
IL302782A (en) 2023-07-01
EP3148589B1 (en) 2024-10-30
WO2015184127A3 (en) 2016-03-17
JP2017519742A (ja) 2017-07-20
ZA201608209B (en) 2023-06-28
IL249197A0 (en) 2017-01-31
IL249197B1 (en) 2024-05-01
IL249197B2 (en) 2024-09-01
CA2950424C (en) 2023-03-14
EP4151234A1 (en) 2023-03-22
US20210330797A1 (en) 2021-10-28
WO2015184127A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MX387604B (es) Formulaciones cannabinoides estables.
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
EP3256149A4 (en) FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
EP4306168A3 (en) Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MY191980A (en) Formulations containing an extract of echinacea and linoleic acid derivatives
ECSP16096831A (es) Derivados de naftiridinadiona
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
JOP20170127A1 (ar) صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
FI20155045A7 (fi) Havupuun pihka steriilin tulehduksen hoitamiseksi ja ennaltaehkäisemiseksi
CL2019002283A1 (es) Composición líquida que contiene pradofloxacina.
MX374540B (es) Desmopresina estabilizada.
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях